{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:23:44Z","timestamp":1790634224487,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,7,10]],"date-time":"2013-07-10T00:00:00Z","timestamp":1373414400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s40261-013-0103-z","type":"journal-article","created":{"date-parts":[[2013,7,9]],"date-time":"2013-07-09T10:07:38Z","timestamp":1373364458000},"page":"589-595","source":"Crossref","is-referenced-by-count":30,"title":["A Clinical Study to Examine the Potential Effect of Lansoprazole on the Pharmacokinetics of Bosutinib when Administered Concomitantly to Healthy Subjects"],"prefix":"10.1007","volume":"33","author":[{"given":"Richat","family":"Abbas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathie","family":"Leister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl","family":"Sonnichsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,10]]},"reference":[{"issue":"10","key":"103_CR1","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110(10):3540\u20136.","journal-title":"Blood"},{"issue":"6","key":"103_CR2","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","volume":"22","author":"A Hochhaus","year":"2008","unstructured":"Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008;22(6):1200\u20136.","journal-title":"Leukemia"},{"issue":"20","key":"103_CR3","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","volume":"26","author":"H Lavallade de","year":"2008","unstructured":"de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26(20):3358\u201363.","journal-title":"J Clin Oncol"},{"issue":"3","key":"103_CR4","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/leu.2008.334","volume":"23","author":"LL Remsing Rix","year":"2009","unstructured":"Remsing Rix LL, Rix U, Colinge J, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia. 2009;23(3):477\u201385.","journal-title":"Leukemia"},{"issue":"23","key":"103_CR5","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","volume":"66","author":"M Puttini","year":"2006","unstructured":"Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006;66(23):11314\u201322.","journal-title":"Cancer Res"},{"issue":"3","key":"103_CR6","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/annonc\/mdr261","volume":"23","author":"M Campone","year":"2012","unstructured":"Campone M, Bondarenko I, Brincat S, et al. Phase II study of single-agent bosutinib, a Src\/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann Oncol. 2012;23(3):610\u20137.","journal-title":"Ann Oncol"},{"issue":"15","key":"103_CR7","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","volume":"119","author":"HJ Khoury","year":"2012","unstructured":"Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure. Blood. 2012;119(15):3403\u201312.","journal-title":"Blood"},{"issue":"28","key":"103_CR8","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","volume":"30","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30(28):3486\u201392.","journal-title":"J Clin Oncol"},{"issue":"17","key":"103_CR9","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","volume":"118","author":"JE Cortes","year":"2011","unstructured":"Cortes JE, Kantarjian HM, Brummendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118(17):4567\u201376.","journal-title":"Blood"},{"key":"103_CR10","unstructured":"BOSULIF\u00ae (bosutinib) tablets, for oral use [package insert]. New York: Pfizer Labs; 2012."},{"issue":"3","key":"103_CR11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1592\/phco.26.3.341","volume":"26","author":"DL Tomilo","year":"2006","unstructured":"Tomilo DL, Smith PF, Ogundele AB, et al. Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy. 2006;26(3):341\u20136.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"103_CR12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00280-011-1688-7","volume":"69","author":"R Abbas","year":"2012","unstructured":"Abbas R, Hug BA, Leister C, et al. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. Cancer Chemother Pharmacol. 2012;69(1):221\u20137.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"103_CR13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1046\/j.1365-2036.1998.00306.x","volume":"12","author":"RA Blum","year":"1998","unstructured":"Blum RA, Hunt RH, Kidd SL, et al. Dose-response relationship of lansoprazole to gastric acid antisecretory effects. Aliment Pharmacol Ther. 1998;12(4):321\u20137.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"103_CR14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/003655299750026335","volume":"34","author":"M Thoring","year":"1999","unstructured":"Thoring M, Hedenstrom H, Eriksson LS. Rapid effect of lansoprazole on intragastric pH: a crossover comparison with omeprazole. Scand J Gastroenterol. 1999;34(4):341\u20135.","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"103_CR15","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1046\/j.1365-2036.1996.103242000.x","volume":"10","author":"NJ Bell","year":"1996","unstructured":"Bell NJ, Hunt RH. Time to maximum effect of lansoprazole on gastric pH in normal male volunteers. Aliment Pharmacol Ther. 1996;10(6):897\u2013904.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"103_CR16","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF00265957","volume":"45","author":"B Delhotal-Landes","year":"1993","unstructured":"Delhotal-Landes B, Flouvat B, Duchier J, et al. Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. Eur J Clin Pharmacol. 1993;45(4):367\u201371.","journal-title":"Eur J Clin Pharmacol"},{"key":"103_CR17","unstructured":"Yannuzzi RV. Validation of an LC\/MS\/MS method for the determination of SKI-606 in human plasma [protocol 05_2756]. Pearl River: Wyeth Research; 2006."},{"issue":"3","key":"103_CR18","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1365-2125.2009.03466.x","volume":"68","author":"MJ Egorin","year":"2009","unstructured":"Egorin MJ, Shah DD, Christner SM, et al. Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. Br J Clin Pharmacol. 2009;68(3):370\u20134.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"103_CR19","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00280-011-1797-3","volume":"69","author":"N Takahashi","year":"2012","unstructured":"Takahashi N, Miura M, Niioka T, et al. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. Cancer Chemother Pharmacol. 2012;69(4):999\u20131004.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"103_CR20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10637-008-9138-z","volume":"27","author":"RL Oostendorp","year":"2009","unstructured":"Oostendorp RL, Buckle T, Beijnen JH, et al. The effect of P-gp (Mdr1a\/1b), BCRP (Bcrp1) and P-gp\/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs. 2009;27(1):31\u201340.","journal-title":"Invest New Drugs"},{"issue":"3","key":"103_CR21","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00280-008-0778-7","volume":"63","author":"BA Sparano","year":"2009","unstructured":"Sparano BA, Egorin MJ, Parise RA, et al. Effect of antacid on imatinib absorption. Cancer Chemother Pharmacol. 2009;63(3):525\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"key":"103_CR22","unstructured":"PREVACID\u00ae (lansoprazole) delayed-release capsules [package insert]. Deerfield: Takeda Pharmaceuticals America, Inc.; 2012."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-013-0103-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-013-0103-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-013-0103-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:28:50Z","timestamp":1559489330000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-013-0103-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,10]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["103"],"URL":"https:\/\/doi.org\/10.1007\/s40261-013-0103-z","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,10]]}}}